Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News For Aug 6, 2019

by Zacks Equity Research

Companies in the news are: AGN, ENR, EPC and MNK

Allergan (AGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Allergan (AGN) delivered earnings and revenue surprises of 0.92% and 3.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Allergan (AGN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is a Beat in Store for Melinta (MLNT) This Earnings Season?

by Zacks Equity Research

Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.

Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.

Allergan (AGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Allergan (AGN) closed at $161.02 in the latest trading session, marking a +0.07% move from the prior day.

Proteostasis (PTI) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.

Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

Should You Buy Allergan (AGN) Ahead of Earnings?

by Zacks Equity Research

Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Guardant Health (GH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.

5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2

by Zacks Equity Research

We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.

What's in the Cards for AcelRx (ACRX) This Earnings Season?

by Zacks Equity Research

AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.

Should You Buy Allergan (AGN) Ahead of Earnings?

by Zacks Equity Research

Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?

by Zacks Equity Research

While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

by Zacks Equity Research

The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.

Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan (AGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Allergan (AGN) closed at $164.26, marking a -1.1% move from the previous day.

Ekta Bagri headshot

Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?

by Ekta Bagri

Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.

Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

by Zacks Equity Research

Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.

J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?

by Zacks Equity Research

J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.